InterAct exhibited at two international conferences: The American Association of Veterinary Laboratory Diagnosticians (AAVLD) annual conference in Reno, USA (18-24 October 2007) and the World Association of Veterinary Laboratory Diagnosticians (WAVLD) annual conference in Melbourne, Australia (11 – 14 November 2007).

The events presented opportunities for InterAct to meet with licensing managers from potential partner companies as well as opportunities to meet other research organisations that may have synergistic IP. For further details of how to contact InterAct and to discuss related opportunities please contact Dr Claude Kaplan (claude.kaplan@ip-pragmatics.com).

A licence identified and completed through InterAct between the UK's Veterinary Laboratories Agency and QIAGEN has won the Outstanding Licensing Deal of the Year in this year's prestigious Animal Pharm awards. The accolade, which was announced at the Animal Pharm Awards ceremony on September 25 at the Gibson Hall in London, is bestowed annually to individuals and organizations who demonstrated remarkable achievements in veterinary health.

For more information on the awards please see the following link: www.animalpharmawards.com

InterAct ran two further workshops in September, including its first joint workshop with a PSRE which is not a member of the partnership. These workshops brought together scientists from across the four partner organisations to discuss common technology opportunities and issues in the fields of geographic information systems (GIS) and biodetection. A number of new opportunities for collaboration and commercial exploitation were identified in each of the workshops. The InterAct project will now prioritise these opportunities and look to identify IP strengths that can be used to form new exploitation vehicles by combining IP across two or more of the partners.

InterAct has completed three further exploitation vehicles bringing the total number to fourteen since the project begun in January 2005. Amongst the recently completed deals is an agreement with DiaSys Corporation's wholly owned subsidiary, DiaSys Europe Limited for the development, validation and commercialization of worm egg counting device, the Veterinary Parasep. As part of the agreement, DiaSys has acquired a license to market the device worldwide. Further validation of the egg testing device is being performed under co-funding proved by the InterAct Proof of Concept Fund.

HPA and CSL will undertake a joint development agreement with Avacta Group plc, which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets.

The agreement is for the joint development of field devices for the rapid detection of micro-organisms and other agents of disease. The goal is to provide a means to assist in the diagnosis and containment of human, animal and plant disease, either natural outbreaks or caused by terrorism. The joint evaluation project will be funded for 12 months by the InterAct project Proof of Concept fund.

See the following link for more details:
http://www.avacta.com/avacta/news_event.asp?news_id=61

InterAct will be exhibiting at the annual AUTM (Association of University Technology Managers) meeting in San Francisco between 7th March and 10th March 2007. The event will be an opportunity for InterAct to meet with licensing managers from potential partner companies as well as an opportunity to meet other research organisations that may have synergistic IP.

InterAct will also be exhibiting at the annual BIO conference in Boston in May 2007. For further details of how to contact InterAct during the conference and to arrange meetings please contact Rupert Osborn (rupert.osborn@ip-pragmatics.com).

InterAct has completed three further exploitation vehicles this month bringing the total number to eleven since the project begun in January 2005.

http://www.csl.gov.uk/newsAndResources/showNews.cfm?id=113 http://www.forsitediagnostics.com